AI-assisted international press reviewPress review

Turner Unveils Emergency Operations Center in Southern California

New emergency operations center in California: a state-of-the-art 60,000 square foot complex to enhance disaster preparedness and response for events like earthquakes and wildfires. Designed by Turner Construction in partnership with Cal OES and DGS, it incorporates sustainable technologies – solar energy, battery storage, and LEED Gold certification – to ensure optimal resilience and protect over 23 million residents in Southern California, with completion expected in 2027. This strategic hub promotes enhanced coordination and decisive action in times of crisis.

Source: Hochtief, published under the title "Turner Breaks Ground on Southern California Emergency Operat..." - 10 November 2025

Recognition of Projects in Singapore for Their Excellence in Safety

Proudly recognized for excellence in safety: our Singaporean projects TR308 (Provision of Electrical Services for Road Tunnels) receive the RoSPA Gold Award, and N103 (North South Corridor from Kampung Java to Suffolk) the Silver Award. Also commended by the Workplace Safety and Health Council for our participation in the WSH Influencer Programme, these accolades highlight our unwavering commitment to a culture of HSE excellence at Leighton Asia, promoting safety every day.

Source: Cimic - 10 November 2025

Novartis Opens Radioligand Therapy Plant in California to Boost Global Expansion

Novartis strengthens its leadership in radioligand therapy with the opening of a new 10,000 square foot facility in Carlsbad, California: a key milestone in its $23 billion investment in US infrastructure, ensuring increased production to meet the growing demand for precision cancer treatments, while planning new sites in Florida and Texas to transform access to innovative care. This expansion, the third site in the US, guarantees reliable and rapid delivery to patients, enhancing the American healthcare ecosystem.

Source: Novartis, published under the title "Novartis opens new radioligand therapy manufacturing facilit..." - 10 November 2025

Bayer Innovates in Sustainable Agritech at COP30 in the Amazon

At COP30, Bayer is transforming a historic building in Belém, forging agreements with Deutsche Bank and Siemens to protect tropical forests, and launching agricultural innovations like the PRO Carbono program covering 3 million hectares—with a 50% reduced carbon footprint—and achieving 100% renewable energy in China by 2026, propelling the shift towards sustainable agriculture and a green future.

Source: Bayer, published under the title "Bayer attends the climate conference in the rainforest" - 9 November 2025

Baxdrostat: Spectacular 14 mmHg Reduction in Resistant Hypertension

Baxdrostat revolutionizes the treatment of resistant hypertension: a significant 14 mmHg reduction in average 24-hour systolic blood pressure observed in the Bax24 trial, with consistent positive effects day and night. Presented at the American Heart Association Scientific Sessions 2025, this drug offers an exemplary safety profile, promising a major breakthrough for millions of patients whose blood pressure remains uncontrolled despite current therapies. Experts like Dr. Bryan Williams highlight its transformative potential to reduce cardiovascular risks.

Source: Astrazeneca, published under the title "Baxdrostat demonstrated a statistically significant and high..." - 8 November 2025

Flavors & Fragrances

TBR Showcases Olfactory Innovation at Household Summit 2025

At the Household Summit 2025 in São Paulo, TBR unveiled olfactory innovations under the theme "Emotional Memory," introducing six fragrances for household products. The event brought together industry experts to discuss technological advancements, sustainability, and emerging trends, highlighting the significance of scents in the user experience.

Source: Takasago, published under the title "Takasago Fragrâncias E Aromas Ltda. (TBR) participated House..." - 7 November 2025

GSK Unveils Major Advances in Liver Diseases at AASLD 2025

GSK presents 21 innovative abstracts on liver disease treatments, leveraging its expertise in inflammation and fibrosis. Promising results from the B-Sure study show a durable functional cure for chronic hepatitis B with bepirovirsen and Peg-IFN, while efimosfermin, administered monthly, improves fibrosis and resolves NASH, paving the way for phase III trials. Liver diseases, responsible for one in 25 deaths worldwide, are finally finding essential therapeutic answers.

Source: Gsk, published under the title "GSK presents data from its advancing liver pipeline at AASLD..." - 7 November 2025

Dupixent Achieves Success Against Allergic Fungal Rhinosinusitis: FDA Prioritizes Review

Sanofi and Regeneron's Dupixent: A Major Breakthrough Against Allergic Fungal Rhinosinusitis. The phase 3 study reveals an impressive reduction in symptoms such as sinus opacification, nasal congestion, and polyps, with a sBLA accepted for priority review by the FDA, aiming for approval in February 2026. If validated, this would be the ninth indication for this innovative treatment of chronic inflammatory diseases. A key step in improving patients' quality of life.

Source: Sanofi, published under the title "Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivota..." - 6 November 2025

DARZALEX FASPRO®: First Approved Therapy for High-Risk Smoldering Myeloma

DARZALEX FASPRO® revolutionizes the treatment of smoldering multiple myeloma: the phase 3 AQUILA study shows a 51% reduction in the risk of progression to active disease or death compared to simple active surveillance. A major breakthrough for early intervention in high-risk patients.

Source: J&j, published under the title "DARZALEX FASPRO® is the first and only treatment approved by..." - 6 November 2025

CAPLYTA®: New Therapy Approved for Major Depressive Disorder

The FDA has approved CAPLYTA® as an adjunct treatment for major depressive disorder, providing an effective and well-tolerated option. Clinical trial results show significant improvement in symptoms, with a low risk of side effects. This advancement could redefine treatment expectations for depression, offering hope for remission to millions of patients.

Source: J&j - 6 November 2025

ADM Celebrates 94 Years of Uninterrupted Dividends in Agritech

ADM celebrates 94 years of innovation in agritech: a dividend of 51 cents per share announced for its 376th consecutive quarterly payment! As a global leader in agricultural supply chains and bio-solutions, ADM reinforces its reliability, supporting food security and sustainability while connecting local needs to global capabilities. Discover how this pioneering company is transforming the future of plant technologies. To learn more, visit adm.com.

Source: Adm, published under the title "ADM Declares Cash Dividend" - 6 November 2025

Nathan Weldon-Bowen: An Indigenous Leader Championing Inclusion at UGL

UGL celebrates Nathan Weldon-Bowen, winner of the Indigenous Employee of the Year award! From his beginnings in Australian football to his key role in construction management, he leads inspiring initiatives for the inclusion of Indigenous and Torres Strait Islander communities. His journey, marked by a family legacy of leadership and advocacy, strengthens UGL's commitment to respect and equality, encouraging young Indigenous professionals to dare and assert themselves. A story of determination and positive impact on the industry and communities.

Source: Cimic - 6 November 2025

Leighton Asia Recognized for Commitment to Safety in Hong Kong

A shining pride for the Hong Kong teams! Leighton Asia triumphs at the HKCA Construction Safety Awards, winning the Proactive Safety Contractor Award for Leighton Contractors (Asia) Ltd and its partners, as well as the Safe Person-in-Charge and Safe Supervisor Awards for talents like Perry Yeung and Seto Choi Leung. These honors celebrate our unwavering HSE culture, promoting safety excellence in the construction sector.

Source: Cimic - 6 November 2025

HOCHTIEF: Profits Rise by 19% and 2025 Guidance Boosted to €780 Million!

HOCHTIEF accelerates its digital transformation: Profits rise by 19% to €538 million, with 2025 guidance revised to €780 million, driven by data centers, green energy, and critical minerals. An ambitious strategy to dominate high-tech and sustainable infrastructure.

Source: Hochtief, published under the title "9M 2025: HOCHTIEF increases profit by 19% and its guidance f..." - 6 November 2025

HOCHTIEF Boosts Profits and Raises Forecasts!

HOCHTIEF strengthens its leadership in high-tech infrastructure: 2025 forecasts revised upwards with an operational net profit of €750 to €780 million, representing a 25% increase! Through a targeted strategy in growth markets, the company doubles its data center orders, secures a major €685 million contract for nuclear works in the UK, and wins the Cleveland Browns stadium project worth $2.4 billion. A push towards digital and energy innovation for a sustainable future.

Source: Grupoacs, published under the title "HOCHTIEF increases its profit and raises its forecasts" - 6 November 2025

HOCHTIEF Raises Its Net Profit Forecast for 2025

HOCHTIEF has revised its operational net profit forecast for 2025 upwards, targeting €750-780 million, representing a 20-25% increase compared to 2024. This acceleration, driven by a dynamic Q4 and the Turner segment, promises solid growth. The interim report for the first nine months will be published today at 14:30 CET. A new milestone for the company in a favorable economic context!

Source: Hochtief, published under the title "HOCHTIEF increases operational net profit guidance for 2025" - 6 November 2025

AstraZeneca: Q3 2025 Results and Growth Outlook

Pascal Soriot, CEO of AstraZeneca, highlighted the company's strong momentum during the first nine months of the year, positioning the firm for sustainable growth through 2026. With 16 positive Phase III clinical trials announced this year, including significant results for baxdrostat, Enhertu, and Datroway, AstraZeneca is also strengthening its operations in the U.S., notably through a historic agreement to reduce drug costs and expanding its production capacity with a new $4.5 billion investment in Virginia.

Source: Astrazeneca, published under the title "9M and Q3 2025 results" - 5 November 2025

Johnson & Johnson at Citi’s 2025 Global Healthcare Conference

Johnson & Johnson takes center stage at Citi’s 2025 Global Healthcare Conference: Join us live for their Fireside Chat on December 3, 2025, at 11:15 AM ET! Follow the event via audio webcast at www.investor.jnj.com, with a replay available 48 hours later. A unique opportunity to explore JNJ's health innovations – Don't miss this essential session!

Source: J&j - 5 November 2025

Soils, Inputs & Water

Nutrien Announces Quarterly Dividend of $0.545 per Share

Nutrien Ltd. has declared a quarterly dividend of $0.545 per share, payable on January 16, 2026. Shareholders of record as of December 31, 2025, will receive their dividend based on their residency, with currency conversion options available. Nutrien, a major player in the agricultural inputs sector, continues to focus on creating long-term value for its shareholders.

Source: Nutrien, published under the title "Nutrien Declares Quarterly Dividend of US$0.545 per Share" - 5 November 2025

Sino-American Soybean Agreement: Markets in Limbo

"The agreement reached between the United States and China could pose significant challenges for the U.S. soybean balance sheet, provided the commitments are honored," says Sébastien Poncelet of Argus Media France. This presents a major risk for global soybean markets.

Source: La France Agricole, published under the title "« Les marchés attendent la mise en œuvre de l’accord sino-am..." - 5 November 2025